Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early clozapine discontinuation risk prediction study
NL-OMON20555Unknown
- Sponsor
- Division of Pharmacoepidemiology & Clinical Pharmacology
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of clozapine in Schizophrenia Spectrum Disorders (SSD), schizophrenia and schizoaffective disorder, sponsored by Division of Pharmacoepidemiology & Clinical Pharmacology. Primary endpoint: Discontinuation of clozapine within 12 months. Status: unknown.
02
Drugs
clozapine
03
Conditions
Schizophrenia Spectrum Disorders (SSD)schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NL-OMON20555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20555.